Zoledronic Acid Concept

Vocabulary Service

MeSH

Overview

subject area of

A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial Journal Articles
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Journal Articles
A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer Journal Articles
Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture Journal Articles
Association between timing of zoledronic acid infusion and hip fracture healing Journal Articles
Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review Journal Articles
Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care — Cancer Care Ontario Clinical Practice Guideline Journal Articles
Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors Journal Articles
Changes in cross‐sectional geometry of the distal femoral metaphysis associated with inflammatory arthritis are reduced by a bisphosphonate (zoledronate) Journal Articles
Clinical Risk Factors for Recurrent Fracture after Hip Fracture: A Prospective Study Journal Articles
Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma Journal Articles
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12 Journal Articles
Effect of bisphosphonates on pain and quality of life in patients with bone metastases Journal Articles
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer Journal Articles
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study Journal Articles
Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical Endpoints Journal Articles
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Journal Articles
Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer Journal Articles
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Journal Articles
Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture Journal Articles
Optimal management of metastatic bone disease Journal Articles
Optimal management of metastatic bone disease Journal Articles
Oral bisphosphonates Journal Articles
Patient Management, and Time and Health Care Resource Utilization Associated with the Use of Intravenous Bisphosphonates For Patients with Metastatic Bone Disease: A Delphi Study Journal Articles
Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study Journal Articles
Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid Conferences
Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer Journal Articles
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update Journal Articles
Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture Journal Articles
Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers Journal Articles
The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair Journal Articles
The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function Conferences
The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy Journal Articles
Time and Labor Costs Associated With Administration of Intravenous Bisphosphonates for Breast or Prostate Cancer Patients With Metastatic Bone Disease: A Time and Motion Study Journal Articles
Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease Journal Articles
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline Journal Articles
Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis Journal Articles
Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis Journal Articles
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials Journal Articles
Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity Journal Articles
Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity Journal Articles
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Journal Articles
Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program Journal Articles
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion Journal Articles
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial Journal Articles
Zoledronic acid use in cancer patients Journal Articles